MedTrace Logo

Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis

NCT01499459 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-03-22

No results posted yet for this study

Summary

This study is aiming to investigate the efficacy of autologous mesenchymal stem cell (MSC) transplantation in 25 randomized patients with liver cirrhosis autologous mesenchymal stem cell will be derived from patients' bone marrows and will be infused via peripheral vein. Liver biopsies will be performed in every patient in the beginning and at 6th month.

Conditions

Interventions

GENETIC

autologous mesenchymal stem cell transplantation

Every patient is given 1x106 MSCs per kg infused via peripheral vein.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

    lead OTHER

Principal Investigators

  • murat kantarcioglu, MD · Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-07-31
Completion
2012-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499459 on ClinicalTrials.gov